Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial

Cristina Cabrera-López, Teresa Martí, Violeta Catalá, Ferran Torres, Silvia Mateu, Jose Ballarín, Roser Torra, Cristina Cabrera-López, Teresa Martí, Violeta Catalá, Ferran Torres, Silvia Mateu, Jose Ballarín, Roser Torra

Abstract

Background: Tuberous sclerosis (TS) is a rare autosomal dominant systemic disease with an estimated prevalence of 1/6000. Renal angiomyolipoma (AML) is a benign tumour with high morbidity frequently present in TS. The aim of the study was to test the effect of rapamycin in reducing the volume of AML in TS.

Methods: Twenty four-month prospective open-label, single arm, unicentre Phases II andIII study. The primary endpoint was to evaluate the effect of treatment on the reduction of at least 50% AML volume from baseline at 24 months. The secondary endpoints were: average tumour reduction, surgical complications, skin lesions and drug safety.The study population comprised 17 patients, aged >10 years who were diagnosed with TS and had ≥1 renal AML >2 cm of diameter and had a serum creatinine < 2mg/dl and urine protein/creatinine ratio < 22.6 mg/mmol. The trial was conducted at Fundació Puigvert. Rapamycin was given to achieve stable plasma levels between 4 and 8 ng/ml. AML volume was estimated using orthogonal measurements by MRI at baseline, 6, 12 and 24 months.

Results: Ten out of 17 patients were success responders for the main outcome -58.8%, 95%CI: 32.9% to 81.6%-. After 6 months of therapy, the mean volume decrease was 55.18% (5.01 standard error (SE); p<0.001) and 66.38% (4.41 SE; p<0.001) at year 1. There was no significant decrease between year 1 and 2. According to RECIST criteria, all patients achieved a partial response at year 1 and all but two had already achieved this partial response after 6 months.The main analysis was performed according to the intention-to-treat principle analysis. Tumour volume was analyzed over time by means of mixed models for repeated measurement analysis. We used the baseline tumour volume as a covariate for the absolute change and percentage change from baseline data. The analysis was performed using SAS version 9.2 software, and the level of significance was established at 0.05 (two-sided).

Conclusions: This study show that mTOR inhibitors are a relatively safe, efficacious and less aggressive alternative than currently available options in the management of AML in TS.

Trial registration: EudraCT number: 2007-005978-30, ClinicalTrials.gov number: NCT0121712.

Trial registration: ClinicalTrials.gov NCT01217125.

Figures

Figure 1
Figure 1
Spaghetti plot for the individual percentage tumour decrease along time.
Figure 2
Figure 2
Angiomyolipoma measured at baseline and after 6 months of treatment.
Figure 3
Figure 3
Facial angiofibromas improvement after 2 years of therapy.

References

    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–1356. doi: 10.1056/NEJMra055323.
    1. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66:924–934. doi: 10.1111/j.1523-1755.2004.00838.x.
    1. Sooriakumaran P. et al.Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010;105:101–106. doi: 10.1111/j.1464-410X.2009.08649.x.
    1. Aydin H. et al.Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol. 2009;33:289–297. doi: 10.1097/PAS.0b013e31817ed7a6.
    1. Van SM. et al.Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–808. doi: 10.1126/science.277.5327.805.
    1. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–1315.
    1. Sancak O. et al.Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13:731–741. doi: 10.1038/sj.ejhg.5201402.
    1. Dabora SL. et al.Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68:64–80. doi: 10.1086/316951.
    1. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24. doi: 10.1038/ng1494.
    1. Dixon WJ, Massey FJ. Introduction to statistical analysis. McGraw-Hill, New York; 1983.
    1. Chernick MRLCY. The saw-toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. Am Stat. 2002;56:149–155. doi: 10.1198/000313002317572835. Ref Type: Magazine Article.
    1. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Springer-Verlag, New York; 2000.
    1. Molenberghs GKM. Missing data in clinical Studies. John Wiley & Sons, Ltd, Chichester, West Susex; 2007.
    1. Therasse P. et al.New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–216. doi: 10.1093/jnci/92.3.205.
    1. Kwiatkowski DJ. et al.A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002;11:525–534. doi: 10.1093/hmg/11.5.525.
    1. Lee L. et al.Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Gene Chromosome Canc. 2005;42:213–227. doi: 10.1002/gcc.20118.
    1. Franz DN. et al.Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490–498. doi: 10.1002/ana.20784.
    1. Wienecke R. et al.Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis. 2006;48:e27–e29. doi: 10.1053/j.ajkd.2006.05.018.
    1. Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail. 2010;32:1233–1236. doi: 10.3109/0886022X.2010.517345.
    1. Peces R. et al.Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant. 2010;25:3787–3791. doi: 10.1093/ndt/gfq456.
    1. Herry I, Neukirch C, Debray MP, Mignon F, Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med. 2007;18:76–77. doi: 10.1016/j.ejim.2006.07.017.
    1. McCormack FX. et al.Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–1606. doi: 10.1056/NEJMoa1100391.
    1. Yalon M, Ben-Sira L, Constantini S, Toren A. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst. 2011;27:179–181. doi: 10.1007/s00381-010-1222-y.
    1. Bissler JJ. et al.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–151. doi: 10.1056/NEJMoa063564.
    1. Davies DM. et al.Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–4081. doi: 10.1158/1078-0432.CCR-11-0445.
    1. Dabora SL. et al.Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and. PLoS One. 2011;6:e23379. doi: 10.1371/journal.pone.0023379.
    1. Cabrera López C. et al.Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. Nefrologia. 2011;31:292–298.
    1. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002;62:5645–5650.
    1. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Canc Cell. 2003;4:147–158. doi: 10.1016/S1535-6108(03)00187-9.
    1. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex: A pilot study of 9 Japanese TSC patients with different disease severity. Br J Dermatol. 2011.
    1. Hofbauer GF. et al.The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159:473–475. doi: 10.1111/j.1365-2133.2008.08677.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe